Glycoprotein IIb/IIIa receptor antagonist (see abstract)

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 2, 2003, Pages 616-623

  Hong, Ting Ting ^a   Driscoll, Edward M ^a   White, Andrew J ^a   Sherigill, Ardaman ^a   Giboulot, Thierry A ^b   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Cephalon France   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2 NAPHTHYLSULFONYL)AMINO] 3 [[2 [[4 (4 PIPERIDINYL) 2 [2 (4 PIPERIDINYL)ETHYL]BUTANOYL]AMINO]ACETYL]AMINO]PROPANOIC ACID; ACETYLSALICYLIC ACID; ALTEPLASE; CRL 42796; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DOG; FEMALE; FIBRINOLYTIC THERAPY; HEMATOLOGICAL PARAMETERS; INTRACORONARY INFUSION; LEFT CORONARY ARTERY; LOW DRUG DOSE; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

ANIMALS; ASPIRIN; BLOOD COAGULATION; CORONARY THROMBOSIS; DIPEPTIDES; DISEASE MODELS, ANIMAL; DOGS; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; HEMODYNAMIC PROCESSES; MALE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; REPERFUSION; SULFONAMIDES; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0041314000     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.052886     Document Type: Article

References (30)

1. Bennett JS (2001) Novel platelet inhibitors. Annu Rev Med 52:161-184.
2. Channing-Rodgers RP and Levine J (1990) A critical reappraisal of the bleeding time. Semin Thromb Hemostasis 16:1-20.
3. Coller BS (1985) A new murine monoclonal antibody reports an activation dependent change in the conformation and/or microenvironment of the platelet GPIIb/IIIa complex. J Clin Investig 75:101-108.
4. Ervin AL and Peerschke EIB (2001) Platelet activation by sustained exposure to low-dose plasmin. Blood Coagul Fibrinolysis 12:415-425.
5. Falk E (1985) Unstable angina with fatal outcome dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 71:699-708.
6. Hennan JK, Hong TT, Willens DE, Driscoll EM, Giboulot TA, and Lucchesi BR (2002) Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796. Br J Pharmacol 136:927-937.
7. Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, and Lucchesi BR (2001) Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104:820-825.
8. Hennan JK, Willens DE, Driscoll EM, Hong T-t, Giboulot T, and Lucchesi BR (2003) Prevention of carotid artery thrombosis after oral administration of the glycoprotein IIb/IIIa antagonist CRL42796. J Cardiovas Pharmacol, in press.
9. Hennekens CH (1990) Role of aspirin with thrombolytic therapy in acute myocardial infarction. Chest 97:151S-155S.
10. Ishii-Watabe A, Uchida E, Mizuguchi H, and Hayakawa T (2000) On the mechanism of plasmin-induced platelet aggregation. Implications of the dual role of granule ADP. Biochem Pharmacol 59:1345-1355.
11. Koller RL (1991) Prevention of recurrent ischemic stroke. Postgrad Med 90:81-84.
12. Kuliopulos A, Covic L, Seely SK, Sheridan PJ, Helin J, and Costello C (1999) Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation and implications for thrombolytic therapy. Biochemistry 38:4572-4585.
13. Lam SC (1992) Isolation and characterization of a cymotryptic fragment of platelet glycoprotein IIb/IIIa retaining Arg-Gly-Asp binding activity. J Biol Chem 267: 5649-5655.
14. Loscalzo J, Pashe B, Quimet H, and Fredman JE (1995) Platelets and plasminogen activation. Thromb Haemost 74:291-293.
15. Makkar RR, Litvack F, Eigler NL, Nakamura M, Ivey PA, Forrester JS, Shah PK, Jordan RE, and Kaul S (1997) Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Circulation 95:1015-1021.
16. Marcus AJ (1994) Cellular interactions of platelets in thrombosis in Thrombosis and Hemorrhage (Loscalzo J and Schafer AI eds) pp 279-291, Boston, Blackwell.
17. Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Laywell E, Kitzen J, and Lucchesi BR (1990) Antiplatelet antibody [7E3 F(ab)2 antibody directed against the platelet GP IIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 21:393-405.
18. Peerschke EI (1985) The platelet fibrinogen receptor. Semin Hematol 22:241-259.
19. Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shatil SJ, Randolph A, Jakubowski JA, Jennings LK, et al. (1997) Effect of calcium on GPIIb/IIIa interactions with integrilin: enhanced GPIIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium. Circulation 96:1488-1494.
20. Plow EF and Ginsberg MH (1989) Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 9:117-156.
21. Rabhi-Sabile S and Pidard D (1995) Exposure of human platelets to plasmin results in expression of irreversibly active fibrinogen receptors. Thromb Haemostas 73: 693-701.
22. Rebello SS, Huang J, Saito K, and Lucchesi BR (1998) The in vivo efficacy of SM-20302, a GPIIb/IIIa receptor antagonist correlates with ex vivo platelet inhibition in heparinized blood but not in citrated blood. Arterioscler Thromb Vasc Biol 18:954-960.
23. Rebello SS, Huang J, Saito K, Saucedo JF, Bates ER, and Lucchesi BR (1999) Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion. Eur J Pharmacol 374:399-410.
24. Romson JL, Haack DW, and Lucchesi BR (1980) Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents. Thromb Res 17:841-853.
25. Rote WE, Davis JH, Mousa SA, Reilly TM, and Lucchesi BR (1994) Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis. J Cardiovas Pharmacol 23:681-689.
26. Smith JB and Willis AL (1971) Aspirin selectively inhibits prostaglandin production in human platelets. Nature (Lond) 231:235-237.
27. Spinler SA, Hilleman DE, Cheng JW, Howard PA, Mauro VF, Lopez LM, Munger MA, Gardner SF, and Nappi JM (2001) New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines. Ann Pharmacother 35:589-617.
28. +2-dependent binding of a synthetic Arg-Gly-Asp (RGD) peptide to a single site on the purified platelet glycoprotein IIb/IIIa complex. J Biol Chem 267:13102-13108.
29. Sudo Y and Lucchesi BR (1996) Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin. J Cardiovasc Pharmacol 27:545-555.
30. Topol EJ (2000) Acute myocardial infarction: thrombolysis. Heart 83:122-126.